Attovia Therapeutics (ATTO) vs Ginkgo Bioworks (DNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Ginkgo Bioworks is the larger company by market cap ($763.6 million vs $744.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATTO | DNA |
|---|---|---|
| Share price | $16.31 | $11.34 |
| Market cap | $744.57M | $763.64M |
| 1-day change | -0.67% | -1.13% |
| YTD return | — | +38.03% |
| 1-year return | — | -22.60% |
| 5-year return | — | -97.59% |
| EPS (TTM) | $-2.74 | $-5.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.00 | $18.22 |
| 52-week low | $15.48 | $5.37 |
| Distance from 52-week high | -41.75% | -37.76% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +158.74% | -38.27% |
| Average volume | 458.24K | 1.77M |
| Shares outstanding | 45.65M | 55.38M |
| Employees | 44 | 485 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Attovia Therapeutics
ATTO stock →Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
Healthcare · Biotechnology · 44 employees
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Healthcare · Biotechnology · 485 employees
ATTO vs DNA FAQ
Which is bigger, Attovia Therapeutics or Ginkgo Bioworks?
Ginkgo Bioworks (DNA) is larger, with a market capitalization of $763.64M compared with $744.57M for Attovia Therapeutics (ATTO).
Are Attovia Therapeutics and Ginkgo Bioworks in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.